- Home
- SMTK vs NERV Comparison
SMTK vs NERV Comparison
Compare SMTK & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTK
- NERV
- Stock Information
- Founded
- SMTK 2009
- NERV 2007
- Country
- SMTK United Kingdom
- NERV United States
- Employees
- SMTK N/A
- NERV N/A
- Industry
- SMTK
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- SMTK
- NERV Health Care
- Exchange
- SMTK NYSE
- NERV Nasdaq
- Market Cap
- SMTK 13.3M
- NERV 10.7M
- IPO Year
- SMTK N/A
- NERV 2014
- Fundamental
- Price
- SMTK $2.75
- NERV $1.64
- Analyst Decision
- SMTK
- NERV Hold
- Analyst Count
- SMTK 0
- NERV 1
- Target Price
- SMTK N/A
- NERV $5.00
- AVG Volume (30 Days)
- SMTK 103.6K
- NERV 15.1K
- Earning Date
- SMTK 05-12-2025
- NERV 04-30-2025
- Dividend Yield
- SMTK N/A
- NERV N/A
- EPS Growth
- SMTK N/A
- NERV N/A
- EPS
- SMTK N/A
- NERV 0.19
- Revenue
- SMTK $82,000.00
- NERV N/A
- Revenue This Year
- SMTK N/A
- NERV N/A
- Revenue Next Year
- SMTK N/A
- NERV N/A
- P/E Ratio
- SMTK N/A
- NERV $8.95
- Revenue Growth
- SMTK 203.70
- NERV N/A
- 52 Week Low
- SMTK $2.01
- NERV $1.42
- 52 Week High
- SMTK $13.00
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- SMTK N/A
- NERV 46.50
- Support Level
- SMTK N/A
- NERV $1.52
- Resistance Level
- SMTK N/A
- NERV $1.80
- Average True Range (ATR)
- SMTK 0.00
- NERV 0.10
- MACD
- SMTK 0.00
- NERV 0.00
- Stochastic Oscillator
- SMTK 0.00
- NERV 43.30
About SMTK SMARTKEM INC
SmartKem Inc focuses on the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors for transistor backplanes. The company's semiconductor platform can be used in a number of applications including mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company derives revenue from the sale of TRUFLEX inks and demonstration products.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.